BioSpace News Archive

Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, is pleased to announce U.S. availability of its SARS-CoV-2 quality assessment products – FDA registration enabling immediate usage by U.S. clinical laboratories to evaluate performance, procedures, and workflow of tests that detect SARS-CoV-2 virus, the causative agent of COVID-19 disease.

Orchard Therapeutics, a global gene therapy leader, announced a new strategic plan to realize the potential of the hematopoietic stem cell gene therapy approach and reported its financial results for the quarter ended March 31, 2020.

Strengthened Board of Directors and expanded leadership team with appointment of General Counsel

Momenta Pharmaceuticals, Inc., a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, reported its financial results for the first quarter ended March 31, 2020.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced its financial and operational results for the first quarter ended March 31, 2020.

Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced that Carla Poulson has joined the company as senior vice president and chief human resources officer.

Newly Published Positive Efficacy Data in an Accepted Model of Huntington’s Disease

Conference call and webcast today at 8:30 a.m. ET Xeris Pharmaceuticals, Inc. today announced financial results for first quarter

Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that Marc E. Uknis MD, FACS has been appointed to serve as Chief Medical Officer, effective today. Dr. Uknis brings more than 35 years of experience in industry and academia in research programs across various areas including surgery,

22nd Century Group, Inc., a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, reported results for the first quarter ended March 31, 2020.